Meet The Team
Board & Executive
Chairman
David Tuch, PhD, brings more than two decades of leadership in healthcare technology to his role as Chairman of Akrivia Health. A seasoned medtech executive, he has a proven track record of building and scaling healthcare companies from early-stage ventures to successful exits. In addition to his role at Akrivia, David serves as Chairman across a portfolio of medical device and digital health organizations. He holds a PhD jointly awarded by MIT and Harvard Medical School and divides his time between Boston and the UK.
“I am thrilled to join Akrivia Health at such a pivotal moment in its growth. The company’s mission to revolutionize mental health and dementia research through groundbreaking data solutions tackles one of healthcare’s greatest challenges. I look forward to partnering with the team to expand Akrivia’s impact and accelerate the future of neuroscience research.”
Co-Founder & Chief Scientific Adviser Professor
Simon is a clinician scientist with a background in cell and molecular neuroscience and a long-standing clinical career in psychiatry, specialising in the mental health of older adults within the NHS. He was the founding Director of the NIHR Biomedical Research Centre for Mental Health and Dementia at the Maudsley and Institute of Psychiatry and later served as Director of Research at King’s Health Partners. Simon was also the founding Academic Lead at the Alzheimer’s Research UK Drug Discovery Institute at the University of Oxford.
His academic leadership spans senior roles at King’s College London and Oxford, where his work focused on translational neuroscience. He later joined Johnson & Johnson, where he led global neuroscience research as Disease Area Stronghold Lead for Neurodegeneration and subsequently Head of Neuroscience Discovery and Translation. He currently serves as Vice President and Distinguished Fellow at J&J. In recognition of his contributions to neuroscience, he was knighted in 2017.
“Over 15 years ago, we developed the first iteration of the CRIS system, convinced that real-world data would play a pivotal role in transforming mental health care and research. That conviction still drives me. Akrivia Health grew from that early success evolving a local platform into a national and soon global, real-world data infrastructure. Today, by integrating genomics and molecular data, Akrivia is enabling a new era of precision neuroscience from redefining disease categories and developing biomarkers, to accelerating drug discovery and improving clinical outcomes.”
Co-founder & Chief Executive Officer
Mike brings over 30 years of experience driving transformative digital and informatics programs across the NHS. He has held senior leadership roles, including Director of Information Strategy at the Oxford Academic Health Science Centre and South London and Maudsley NHS Foundation Trust.
A recognized innovator in healthcare data, Mike initiated and led the UK-CRIS (Clinical Record Interactive Search) program under the National Institute for Health Research, securing significant funding from NIHR and Innovate UK and laying the foundation for the creation of Akrivia Health. He has since helped guide Akrivia through a successful Series A funding round and continues to shape its strategic direction as the company scales its impact across the NHS and life sciences sectors.
“I have dedicated my career to advancing digital and data innovation within the NHS, so co-founding Akrivia was a natural next step. Akrivia’s mission to transform mental health and dementia research through powerful, real-world data addresses a critical need in healthcare. It is inspiring to see how our work is already making a difference for patients, clinicians and researchers.”
Co-Founder & Chief Business Officer
David is the Co-Founder and Chief Business Officer of Akrivia Health, an AI-driven neuroscience company spun out of the University of Oxford. With expertise spanning neuroscience, healthcare, data privacy and artificial intelligence, he has led Akrivia’s growth from inception to a 50-plus-person organisation, raising more than £30 million in investment and building a network of over 20 NHS Trusts.
David’s leadership has been instrumental in shaping Akrivia’s impact on mental health and dementia research, driving innovation that bridges academic, clinical and industry perspectives. Before Akrivia, he held roles across the NHS, academia and industry, including positions at King’s College London and South London and Maudsley NHS Foundation Trust, as well as founding a Privacy & Digital Health consultancy. His work has earned multiple industry awards and has been published in leading journals such as the International Journal of Geriatric Psychiatry and BMC Psychiatry.
“I helped co-found Akrivia to unite data, expertise and technology in a way that could truly transform research and outcomes for people living with psychiatric and neurodegenerative conditions. Our goal is to create the step change that mental health and dementia research has long needed.”
Board Member
Hailey has built her career at the intersection of health technology and data analytics. At Tempus AI she helped establish the company’s core data infrastructure and led development of its early clinician- and life sciences-facing analytic tools. More recently, she has expanded Tempus’ platform into neuropsychiatry enabling more personalised, data-driven treatment decisions to improve patient outcomes.
“I am excited by Akrivia’s complementary mission and global approach and see the company as uniquely positioned to transform care by fostering collaboration between researchers and clinicians.”
Board Member (University of Oxford Board Member)
Steve is Deputy Head of Life Sciences at Oxford University Innovation where he leads the digital health and medical technologies team. He was previously Senior Investment Manager responsible for managing the University’s equity interests in its portfolio of life sciences spinouts. With a background in venture capital investing in university spinouts across Australasia he has also held executive and governance roles in high-growth companies for more than 20 years.
“I am particularly excited by Akrivia’s pioneering use of large, multi-source datasets to deliver new insights and personalised treatments in mental health and dementia- areas of immense need where innovation can transform patient outcomes.”
Board Observer
Lyle serves as a Board Observer at Akrivia Health and is a member of the Remuneration Committee. He is a Portfolio Manager at Future Planet Capital, a global impact-led venture firm managing over $450 million. Lyle focuses on investments in science and technology from leading universities with experience across growth equity, venture, and secondary transactions in climate, health and deep tech.
“I am particularly excited by Akrivia’s transition from UK academic excellence to a global platform, supported by its US rollout and strategic infrastructure partnerships. This is exactly the kind of scalable, mission-driven opportunity that Future Planet Capital seeks to back and grow.”
Head of People & Organisational Development
Amy leads Akrivia Health’s People function, driving HR strategy, talent acquisition, organisational development and employee engagement. She plays a central role in building a high-performing, mission-driven culture that supports the company’s rapid growth and ambition.
With more than a decade of experience across the life sciences, NHS and technology sectors, Amy brings deep expertise in organisational design, workforce planning and culture development. Her leadership ensures that Akrivia continues to attract, develop and retain exceptional talent as it scales its impact in mental health and dementia research.
“I joined Akrivia to help shape a pioneering company redefining how mental health and dementia are understood and addressed. Putting people and purpose at the heart of everything we do is key to our success.”
Chief Medical Officer
Philip heads Akrivia Health’s collaborations with healthcare organisations, driving forward partnerships that enable meaningful impact. He plays a central role in shaping and delivering our clinical research programmes, ensuring they not only advance knowledge but also translate directly into better care. With extensive experience across clinical practice and academic mental health research, Philip is passionate about turning insights into real-world improvements for patients and services.
“I joined Akrivia Health to help the company use its innovative technologies and unique database to advance the assessment and treatment of people with mental health problems and dementia.”
Faces Behind Akrivia
Meet The Team
Board of Directors
Chairman
David Tuch, PhD, brings more than two decades of leadership in healthcare technology to his role as Chairman of Akrivia Health. A seasoned medtech executive, he has a proven track record of building and scaling healthcare companies from early-stage ventures to successful exits. In addition to his role at Akrivia, David serves as Chairman across a portfolio of medical device and digital health organizations. He holds a PhD jointly awarded by MIT and Harvard Medical School and divides his time between Boston and the UK.
“I am thrilled to join Akrivia Health at such a pivotal moment in its growth. The company’s mission to revolutionize mental health and dementia research through groundbreaking data solutions tackles one of healthcare’s greatest challenges. I look forward to partnering with the team to expand Akrivia’s impact and accelerate the future of neuroscience research.”
Co-Founder & Chief Scientific Adviser Professor
Simon is a clinician scientist with a background in cell and molecular neuroscience and a long-standing clinical career in psychiatry, specialising in the mental health of older adults within the NHS. He was the founding Director of the NIHR Biomedical Research Centre for Mental Health and Dementia at the Maudsley and Institute of Psychiatry and later served as Director of Research at King’s Health Partners. Simon was also the founding Academic Lead at the Alzheimer’s Research UK Drug Discovery Institute at the University of Oxford.
His academic leadership spans senior roles at King’s College London and Oxford, where his work focused on translational neuroscience. He later joined Johnson & Johnson, where he led global neuroscience research as Disease Area Stronghold Lead for Neurodegeneration and subsequently Head of Neuroscience Discovery and Translation. He currently serves as Vice President and Distinguished Fellow at J&J. In recognition of his contributions to neuroscience, he was knighted in 2017.
“Over 15 years ago, we developed the first iteration of the CRIS system, convinced that real-world data would play a pivotal role in transforming mental health care and research. That conviction still drives me. Akrivia Health grew from that early success evolving a local platform into a national and soon global, real-world data infrastructure. Today, by integrating genomics and molecular data, Akrivia is enabling a new era of precision neuroscience from redefining disease categories and developing biomarkers, to accelerating drug discovery and improving clinical outcomes.”
Co-founder & Chief Executive Officer
Mike brings over 30 years of experience driving transformative digital and informatics programs across the NHS. He has held senior leadership roles, including Director of Information Strategy at the Oxford Academic Health Science Centre and South London and Maudsley NHS Foundation Trust.
A recognized innovator in healthcare data, Mike initiated and led the UK-CRIS (Clinical Record Interactive Search) program under the National Institute for Health Research, securing significant funding from NIHR and Innovate UK and laying the foundation for the creation of Akrivia Health. He has since helped guide Akrivia through a successful Series A funding round and continues to shape its strategic direction as the company scales its impact across the NHS and life sciences sectors.
“I have dedicated my career to advancing digital and data innovation within the NHS, so co-founding Akrivia was a natural next step. Akrivia’s mission to transform mental health and dementia research through powerful, real-world data addresses a critical need in healthcare. It is inspiring to see how our work is already making a difference for patients, clinicians and researchers.”
Co-Founder & Chief Business Officer
David is the Co-Founder and Chief Business Officer of Akrivia Health, an AI-driven neuroscience company spun out of the University of Oxford. With expertise spanning neuroscience, healthcare, data privacy and artificial intelligence, he has led Akrivia’s growth from inception to a 50-plus-person organisation, raising more than £30 million in investment and building a network of over 20 NHS Trusts.
David’s leadership has been instrumental in shaping Akrivia’s impact on mental health and dementia research, driving innovation that bridges academic, clinical and industry perspectives. Before Akrivia, he held roles across the NHS, academia and industry, including positions at King’s College London and South London and Maudsley NHS Foundation Trust, as well as founding a Privacy & Digital Health consultancy. His work has earned multiple industry awards and has been published in leading journals such as the International Journal of Geriatric Psychiatry and BMC Psychiatry.
“I helped co-found Akrivia to unite data, expertise and technology in a way that could truly transform research and outcomes for people living with psychiatric and neurodegenerative conditions. Our goal is to create the step change that mental health and dementia research has long needed.”
Board Members
Board Member
Hailey has built her career at the intersection of health technology and data analytics. At Tempus AI she helped establish the company’s core data infrastructure and led development of its early clinician- and life sciences-facing analytic tools. More recently, she has expanded Tempus’ platform into neuropsychiatry enabling more personalised, data-driven treatment decisions to improve patient outcomes.
“I am excited by Akrivia’s complementary mission and global approach and see the company as uniquely positioned to transform care by fostering collaboration between researchers and clinicians.”
Board Member (University of Oxford Board Member)
Steve is Deputy Head of Life Sciences at Oxford University Innovation where he leads the digital health and medical technologies team. He was previously Senior Investment Manager responsible for managing the University’s equity interests in its portfolio of life sciences spinouts. With a background in venture capital investing in university spinouts across Australasia he has also held executive and governance roles in high-growth companies for more than 20 years.
“I am particularly excited by Akrivia’s pioneering use of large, multi-source datasets to deliver new insights and personalised treatments in mental health and dementia- areas of immense need where innovation can transform patient outcomes.”
Board Observer
Lyle serves as a Board Observer at Akrivia Health and is a member of the Remuneration Committee. He is a Portfolio Manager at Future Planet Capital, a global impact-led venture firm managing over $450 million. Lyle focuses on investments in science and technology from leading universities with experience across growth equity, venture, and secondary transactions in climate, health and deep tech.
“I am particularly excited by Akrivia’s transition from UK academic excellence to a global platform, supported by its US rollout and strategic infrastructure partnerships. This is exactly the kind of scalable, mission-driven opportunity that Future Planet Capital seeks to back and grow.”
Executive Team
Co-Founder & Chief Scientific Adviser Professor
Simon is a clinician scientist with a background in cell and molecular neuroscience and a long-standing clinical career in psychiatry, specialising in the mental health of older adults within the NHS. He was the founding Director of the NIHR Biomedical Research Centre for Mental Health and Dementia at the Maudsley and Institute of Psychiatry and later served as Director of Research at King’s Health Partners. Simon was also the founding Academic Lead at the Alzheimer’s Research UK Drug Discovery Institute at the University of Oxford.
His academic leadership spans senior roles at King’s College London and Oxford, where his work focused on translational neuroscience. He later joined Johnson & Johnson, where he led global neuroscience research as Disease Area Stronghold Lead for Neurodegeneration and subsequently Head of Neuroscience Discovery and Translation. He currently serves as Vice President and Distinguished Fellow at J&J. In recognition of his contributions to neuroscience, he was knighted in 2017.
“Over 15 years ago, we developed the first iteration of the CRIS system, convinced that real-world data would play a pivotal role in transforming mental health care and research. That conviction still drives me. Akrivia Health grew from that early success evolving a local platform into a national and soon global, real-world data infrastructure. Today, by integrating genomics and molecular data, Akrivia is enabling a new era of precision neuroscience from redefining disease categories and developing biomarkers, to accelerating drug discovery and improving clinical outcomes.”
Co-founder & Chief Executive Officer
Mike brings over 30 years of experience driving transformative digital and informatics programs across the NHS. He has held senior leadership roles, including Director of Information Strategy at the Oxford Academic Health Science Centre and South London and Maudsley NHS Foundation Trust.
A recognized innovator in healthcare data, Mike initiated and led the UK-CRIS (Clinical Record Interactive Search) program under the National Institute for Health Research, securing significant funding from NIHR and Innovate UK and laying the foundation for the creation of Akrivia Health. He has since helped guide Akrivia through a successful Series A funding round and continues to shape its strategic direction as the company scales its impact across the NHS and life sciences sectors.
“I have dedicated my career to advancing digital and data innovation within the NHS, so co-founding Akrivia was a natural next step. Akrivia’s mission to transform mental health and dementia research through powerful, real-world data addresses a critical need in healthcare. It is inspiring to see how our work is already making a difference for patients, clinicians and researchers.”
Co-Founder & Chief Business Officer
David is the Co-Founder and Chief Business Officer of Akrivia Health, an AI-driven neuroscience company spun out of the University of Oxford. With expertise spanning neuroscience, healthcare, data privacy and artificial intelligence, he has led Akrivia’s growth from inception to a 50-plus-person organisation, raising more than £30 million in investment and building a network of over 20 NHS Trusts.
David’s leadership has been instrumental in shaping Akrivia’s impact on mental health and dementia research, driving innovation that bridges academic, clinical and industry perspectives. Before Akrivia, he held roles across the NHS, academia and industry, including positions at King’s College London and South London and Maudsley NHS Foundation Trust, as well as founding a Privacy & Digital Health consultancy. His work has earned multiple industry awards and has been published in leading journals such as the International Journal of Geriatric Psychiatry and BMC Psychiatry.
“I helped co-found Akrivia to unite data, expertise and technology in a way that could truly transform research and outcomes for people living with psychiatric and neurodegenerative conditions. Our goal is to create the step change that mental health and dementia research has long needed.”
Head of People & Organisational Development
Amy leads Akrivia Health’s People function, driving HR strategy, talent acquisition, organisational development and employee engagement. She plays a central role in building a high-performing, mission-driven culture that supports the company’s rapid growth and ambition.
With more than a decade of experience across the life sciences, NHS and technology sectors, Amy brings deep expertise in organisational design, workforce planning and culture development. Her leadership ensures that Akrivia continues to attract, develop and retain exceptional talent as it scales its impact in mental health and dementia research.
“I joined Akrivia to help shape a pioneering company redefining how mental health and dementia are understood and addressed. Putting people and purpose at the heart of everything we do is key to our success.”
Chief Medical Officer
Philip heads Akrivia Health’s collaborations with healthcare organisations, driving forward partnerships that enable meaningful impact. He plays a central role in shaping and delivering our clinical research programmes, ensuring they not only advance knowledge but also translate directly into better care. With extensive experience across clinical practice and academic mental health research, Philip is passionate about turning insights into real-world improvements for patients and services.
“I joined Akrivia Health to help the company use its innovative technologies and unique database to advance the assessment and treatment of people with mental health problems and dementia.”
Board & Executive
Chairman
David Tuch, PhD, brings more than two decades of leadership in healthcare technology to his role as Chairman of Akrivia Health. A seasoned medtech executive, he has a proven track record of building and scaling healthcare companies from early-stage ventures to successful exits. In addition to his role at Akrivia, David serves as Chairman across a portfolio of medical device and digital health organizations. He holds a PhD jointly awarded by MIT and Harvard Medical School and divides his time between Boston and the UK.
“I am thrilled to join Akrivia Health at such a pivotal moment in its growth. The company’s mission to revolutionize mental health and dementia research through groundbreaking data solutions tackles one of healthcare’s greatest challenges. I look forward to partnering with the team to expand Akrivia’s impact and accelerate the future of neuroscience research.”
Co-Founder & Chief Scientific Adviser Professor
Simon is a clinician scientist with a background in cell and molecular neuroscience and a long-standing clinical career in psychiatry, specialising in the mental health of older adults within the NHS. He was the founding Director of the NIHR Biomedical Research Centre for Mental Health and Dementia at the Maudsley and Institute of Psychiatry and later served as Director of Research at King’s Health Partners. Simon was also the founding Academic Lead at the Alzheimer’s Research UK Drug Discovery Institute at the University of Oxford.
His academic leadership spans senior roles at King’s College London and Oxford, where his work focused on translational neuroscience. He later joined Johnson & Johnson, where he led global neuroscience research as Disease Area Stronghold Lead for Neurodegeneration and subsequently Head of Neuroscience Discovery and Translation. He currently serves as Vice President and Distinguished Fellow at J&J. In recognition of his contributions to neuroscience, he was knighted in 2017.
“Over 15 years ago, we developed the first iteration of the CRIS system, convinced that real-world data would play a pivotal role in transforming mental health care and research. That conviction still drives me. Akrivia Health grew from that early success evolving a local platform into a national and soon global, real-world data infrastructure. Today, by integrating genomics and molecular data, Akrivia is enabling a new era of precision neuroscience from redefining disease categories and developing biomarkers, to accelerating drug discovery and improving clinical outcomes.”
Co-founder & Chief Executive Officer
Mike brings over 30 years of experience driving transformative digital and informatics programs across the NHS. He has held senior leadership roles, including Director of Information Strategy at the Oxford Academic Health Science Centre and South London and Maudsley NHS Foundation Trust.
A recognized innovator in healthcare data, Mike initiated and led the UK-CRIS (Clinical Record Interactive Search) program under the National Institute for Health Research, securing significant funding from NIHR and Innovate UK and laying the foundation for the creation of Akrivia Health. He has since helped guide Akrivia through a successful Series A funding round and continues to shape its strategic direction as the company scales its impact across the NHS and life sciences sectors.
“I have dedicated my career to advancing digital and data innovation within the NHS, so co-founding Akrivia was a natural next step. Akrivia’s mission to transform mental health and dementia research through powerful, real-world data addresses a critical need in healthcare. It is inspiring to see how our work is already making a difference for patients, clinicians and researchers.”
Co-Founder & Chief Business Officer
David is the Co-Founder and Chief Business Officer of Akrivia Health, an AI-driven neuroscience company spun out of the University of Oxford. With expertise spanning neuroscience, healthcare, data privacy and artificial intelligence, he has led Akrivia’s growth from inception to a 50-plus-person organisation, raising more than £30 million in investment and building a network of over 20 NHS Trusts.
David’s leadership has been instrumental in shaping Akrivia’s impact on mental health and dementia research, driving innovation that bridges academic, clinical and industry perspectives. Before Akrivia, he held roles across the NHS, academia and industry, including positions at King’s College London and South London and Maudsley NHS Foundation Trust, as well as founding a Privacy & Digital Health consultancy. His work has earned multiple industry awards and has been published in leading journals such as the International Journal of Geriatric Psychiatry and BMC Psychiatry.
“I helped co-found Akrivia to unite data, expertise and technology in a way that could truly transform research and outcomes for people living with psychiatric and neurodegenerative conditions. Our goal is to create the step change that mental health and dementia research has long needed.”
Board Member
Hailey has built her career at the intersection of health technology and data analytics. At Tempus AI she helped establish the company’s core data infrastructure and led development of its early clinician- and life sciences-facing analytic tools. More recently, she has expanded Tempus’ platform into neuropsychiatry enabling more personalised, data-driven treatment decisions to improve patient outcomes.
“I am excited by Akrivia’s complementary mission and global approach and see the company as uniquely positioned to transform care by fostering collaboration between researchers and clinicians.”
Board Member (University of Oxford Board Member)
Steve is Deputy Head of Life Sciences at Oxford University Innovation where he leads the digital health and medical technologies team. He was previously Senior Investment Manager responsible for managing the University’s equity interests in its portfolio of life sciences spinouts. With a background in venture capital investing in university spinouts across Australasia he has also held executive and governance roles in high-growth companies for more than 20 years.
“I am particularly excited by Akrivia’s pioneering use of large, multi-source datasets to deliver new insights and personalised treatments in mental health and dementia- areas of immense need where innovation can transform patient outcomes.”
Board Observer
Lyle serves as a Board Observer at Akrivia Health and is a member of the Remuneration Committee. He is a Portfolio Manager at Future Planet Capital, a global impact-led venture firm managing over $450 million. Lyle focuses on investments in science and technology from leading universities with experience across growth equity, venture, and secondary transactions in climate, health and deep tech.
“I am particularly excited by Akrivia’s transition from UK academic excellence to a global platform, supported by its US rollout and strategic infrastructure partnerships. This is exactly the kind of scalable, mission-driven opportunity that Future Planet Capital seeks to back and grow.”
Head of People & Organisational Development
Amy leads Akrivia Health’s People function, driving HR strategy, talent acquisition, organisational development and employee engagement. She plays a central role in building a high-performing, mission-driven culture that supports the company’s rapid growth and ambition.
With more than a decade of experience across the life sciences, NHS and technology sectors, Amy brings deep expertise in organisational design, workforce planning and culture development. Her leadership ensures that Akrivia continues to attract, develop and retain exceptional talent as it scales its impact in mental health and dementia research.
“I joined Akrivia to help shape a pioneering company redefining how mental health and dementia are understood and addressed. Putting people and purpose at the heart of everything we do is key to our success.”
Chief Medical Officer
Philip heads Akrivia Health’s collaborations with healthcare organisations, driving forward partnerships that enable meaningful impact. He plays a central role in shaping and delivering our clinical research programmes, ensuring they not only advance knowledge but also translate directly into better care. With extensive experience across clinical practice and academic mental health research, Philip is passionate about turning insights into real-world improvements for patients and services.
“I joined Akrivia Health to help the company use its innovative technologies and unique database to advance the assessment and treatment of people with mental health problems and dementia.”
Senior Leadership Team
Global Commercial Director
Sanjeev is the Global Commercial Director at Akrivia Health, where he leads global commercial strategy to drive partnerships and innovation in mental health and neuroscience research. With over 35 years of experience in the pharmaceutical, biotech and medical device industries, he has a strong track record of scaling companies, raising capital and driving international growth.
He played a pivotal role in the European expansion of Nycomed, working alongside Blackstone and Nordic Capital, which led to the acquisition of Altana AG and Nycomed’s subsequent $11 billion acquisition by Takeda. Sanjeev also built and expanded the global operations of Azanta A/S, culminating in its acquisition by Norgine.
Earlier in his career, he founded and scaled several successful ventures, including Ethical Generics (Bayer AG’s generic medicines division), Trinity Pharma (now part of Trinity Chiesi), Nycomed, and Azanta A/S.
Sanjeev’s expertise spans specialist medicines, orphan drugs, and global product launches across numerous therapeutic areas. At Akrivia, he applies his deep industry knowledge to build strategic partnerships and advance the company’s mission to transform mental health and dementia research through real-world data and AI-driven insights.
“After decades of building and scaling companies across pharma and biotech, I’ve seen both the promise of innovation and the barriers that slow progress in mental health and neuroscience.
I joined Akrivia Health to help change that. By using real-world data and AI, we can accelerate research, unlock insights into conditions like dementia, and ultimately improve outcomes for patients worldwide.”
Director of Research
Ben is Director of R&D at Akrivia Health, leading the company’s research and data strategy. His team curates a unique dataset of six million+ anonymised psychiatric health records, enabling real-world evidence research to improve mental health and dementia care.
They also develop Akrivia’s natural language processing (NLP) pipeline, transforming unstructured clinical notes into secure, structured data that protects privacy and powers meaningful insights.
With expertise in real-world data, AI-driven privacy, precision psychiatry and the social determinants of health, Ben’s team drives research that delivers better outcomes for patients and communities.
“I joined Akrivia Health to help tackle the complex challenges of mental health and dementia at scale. These conditions are shaped by both biological and social factors, yet research and care often miss this complexity.
At Akrivia, our data, tools and partnerships bring together diverse expertise to improve services, inform policy and make a real difference for individuals, families and communities.”
Head of Programmes
Byron is Head of Programmes at Akrivia Health leading the company’s flagship precision neuroscience initiative, GlobalMinds. With a background in public health research and programme delivery, he has extensive experience in developing and implementing interventions to improve health outcomes and reduce inequalities.
Byron began his career in 2009 at the Medical Research Council before spending over a decade at the University of Bristol, where he focused on designing and evaluating evidence-based public health initiatives. At Akrivia, he drives the operational strategy and delivery of GlobalMinds working at the intersection of research, clinical practice and innovation to transform mental health and dementia care.
“I joined Akrivia Health because I saw an opportunity to create meaningful impact at scale for people living with mental health and neurodegenerative conditions, as well as their families and caregivers. These conditions affect millions worldwide yet progress in research and care has often been fragmented and slow. By bringing together cutting-edge data science, clinical expertise and a collaborative network across the NHS and beyond, Akrivia offers a unique chance to drive real change.
For me, this is about more than advancing science, it is about transforming the way we understand, diagnose and treat these conditions, improving outcomes for individuals and reducing the burden on families and health systems globally.”
Head of Legal
Molly Farrow serves as Head of Legal at Akrivia Health, where she directs the company’s commercial contracting, intellectual property protection regime and information governance strategies. Reporting to the CFO, she is focused on scaling Akrivia’s legal operations to support its growth within the complex healthtech and life sciences landscape.
Molly originally trained as a barrister and was called to the Bar of England and Wales in 2020. However, by this time, Molly had discovered a passion for high-growth technology companies, having built the data protection framework for an EdTech start-up over the Coronavirus pandemic. She brought this expertise to Akrivia Health in 2022, initially joining as a compliance officer with a broad remit that spanned from information governance to HR operations.
She was appointed Head of Legal in May 2025 and is now on track to qualify as a solicitor in 2026.
“I have a profound personal connection to Akrivia’s mission to accelerate dementia research, a cause that has deeply affected my family. I channel this motivation into my work by focusing on building robust legal infrastructure to ensure the long-term viability of the company’s transformative research. I also hugely enjoy environments that demand pragmatic problem-solving and creation of scalable and efficient systems, especially those befitting a pioneering precision neuroscience company like Akrivia Health.”
Head of AI & Data Engineering
Luke Fernando brings together a unique mix of philosophical insight, quantitative rigor and hands-on technical expertise. His academic journey spans Philosophy and Mathematics (BA), Financial Engineering (MSc), and Cognitive Neuroscience (MSc) reflecting a deep curiosity about both human thought and complex systems.
At Akrivia Health, Luke applies this breadth of experience to the design of secure, scalable data platforms and advanced analytics. With a focus on cloud architecture, data engineering and large-scale analytics, he develops solutions that transform complex mental health data into actionable insights. His work helps researchers and partners unlock a deeper understanding of mental health, ultimately driving improvements in patient care and outcomes.
Luke joined Akrivia Health to help transform how mental health data is used to improve patient care. Motivated by Akrivia’s mission, he saw an opportunity to apply his expertise in cloud architecture and data engineering to build platforms that turn complex clinical data into actionable insights, driving meaningful impact for researchers, clinicians and patients.